Longitude Without Time

Luce, J.W. 한국항해항만학회 1978 한국항해학회지 Vol.2 No.1

전기사업의 책임 : 새로운 사조(미국)

Charles F. Luce 대한전기협회 1970 電氣協會誌 Vol.- No.20

Effects of Dexamethasone on the Incidence of Acute Mountain Sickness at Two Intermediate Altitudes

Montgomery, A. Bruce,Luce, John M.,Michael, Phillip,Mills, John MediMedia Korea 1989 JAMA-Korea Vol.4 No.4

Follow-Up Consultations for Cervical Cancer Patients in a Mexican Cancer Center. Comparison with NCCN Guidelines

Serrano-Olvera, Alberto,Cetina, Lucely,Coronel, Jaime,Duenas-Gonzalez, Alfonso Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.20

Purpose: This study aimed to determine the patterns of follow-up visits for cervix cancer in a national cancer center in Mexico. Materials and Methods: The National Cancer Institute of Mexico is cancer center with 119 beds that mostly cares for an underserved and socially disadvantaged population. The medical records of cases of cervical cancer that had at least one year of clinical follow-up after being in complete response at the end of primary treatment were analyzed. We recorded the numbers of total and yearly follow-up visits and these were compared with the number of follow-up visits recommended by the National Comprehensive Cancer Network 2013, version 2 for cervical cancer. Results: Between March and June 2007, the medical records of 96 consecutive patients were reviewed. Twenty (21%) of these met inclusion criteria and were selected. In the first year the median number of visits was 11 (4-20). In the ensuing years, $2^{nd}$, $3^{rd}$, $4^{th}$ and $5^{th}$, the number of analyzed patients remaining in follow-up decreased to 17, 14, 13 and 9 respectively. There were 462 follow-up visits to primary treating services (Gynecology Oncology, Radiation Oncology and Medical Oncology) as compared to 220 suggested by the NCCN guidelines ($X^2$ test p<0.0001). There were 150 additional visits to other services. Conclusions: Our results suggest that in our institution there is an overuse of oncological services by cervical cancer patients once treatment is completed.

Infrared Scanning Near-Field Optical Microscopy (IR-SNOM) Below the Diffraction Limit

J,S,Sanghera,I,D,Aggarwal,A,Cricenti,R,Generossi,M,Luce,P,Perfetti,G,Margoritondo,N,Tolk,D,Piston 한국세라믹학회 2007 세라미스트 Vol.10 No.3

Infrared Scanning Near-field Optical Microscopy (IR-SNOM) is an extremely powerful analytical instrument since it combines IR spectroscopy’s high chemical specificity with SNOM’s high spatial resolution. In order to do this in the infrared, specialty chalcogenide glass fibers were fabricated and their ends tapered to generate SNOM probes. The fiber tips were installed in a modified near field microscope and both inorganic and biological samples illuminated with the tunable output from a free-electron laser located at Vanderbilt University. Both topographical and IR spectral images were simultaneously recorded with a resolution of ~50 nm and ~100 nm, respectively. Unique spectroscopic features were identified in all samples, with spectral images exhibiting resolutions of up to μ60, or at least 30 times better than the diffraction limited lens-based microscopes. We believe that IR-SNOM can provide a very powerful insight into some of the most important bio-medical research topics.

Simulation of the hybrid and steady state advanced operating modes in ITER

Kessel, C.E.,Giruzzi, G.,Sips, A.C.C.,Budny, R.V.,Artaud, J.F.,Basiuk, V.,Imbeaux, F.,Joffrin, E.,Schneider, M.,Murakami, M.,Luce, T.,St John, Holger,Oikawa, T.,Hayashi, N.,Takizuka, T.,Ozeki, T.,Na, International Atomic Energy Agency 2007 Nuclear fusion Vol.47 No.9

<P>Integrated simulations are performed to establish a physics basis, in conjunction with present tokamak experiments, for the operating modes in the International Thermonuclear Experimental Reactor (ITER). Simulations of the hybrid mode are done using both fixed and free-boundary 1.5D transport evolution codes including CRONOS, ONETWO, TSC/TRANSP, TOPICS and ASTRA. The hybrid operating mode is simulated using the GLF23 and CDBM05 energy transport models. The injected powers are limited to the negative ion neutral beam, ion cyclotron and electron cyclotron heating systems. Several plasma parameters and source parameters are specified for the hybrid cases to provide a comparison of 1.5D core transport modelling assumptions, source physics modelling assumptions, as well as numerous peripheral physics modelling. Initial results indicate that very strict guidelines will need to be imposed on the application of GLF23, for example, to make useful comparisons. Some of the variations among the simulations are due to source models which vary widely among the codes used. In addition, there are a number of peripheral physics models that should be examined, some of which include fusion power production, bootstrap current, treatment of fast particles and treatment of impurities. The hybrid simulations project to fusion gains of 5.6–8.3, β<SUB>N</SUB> values of 2.1–2.6 and fusion powers ranging from 350 to 500 MW, under the assumptions outlined in section 3. Simulations of the steady state operating mode are done with the same 1.5D transport evolution codes cited above, except the ASTRA code. In these cases the energy transport model is more difficult to prescribe, so that energy confinement models will range from theory based to empirically based. The injected powers include the same sources as used for the hybrid with the possible addition of lower hybrid. The simulations of the steady state mode project to fusion gains of 3.5–7, β<SUB>N</SUB> values of 2.3–3.0 and fusion powers of 290 to 415 MW, under the assumptions described in section 4. These simulations will be presented and compared with particular focus on the resulting temperature profiles, source profiles and peripheral physics profiles. The steady state simulations are at an early stage and are focused on developing a range of safety factor profiles with 100% non-inductive current.</P>

Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities

Hasan Brau-Figueroa,Eder Arango-Bravo,Denisse Castro-Eguiluz,Tatiana Galicia-Carmona,Leopoldo Abraham Lugo-Alferez,Ivette Cruz-Bautista,Roberto Jiménez-Lima,Lucely Cetina-Pérez 대한암학회 2022 Cancer Research and Treatment Vol.54 No.2

Purpose The standard treatment for locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy with cisplatin (CDDP) followed by brachytherapy. The presence of comorbidities are risk factors for nephrotoxicity and are associated with lower survival. Gemcitabine is a radiosensitizing drug that has shown efficacy and safety in this context. The effectiveness of concomitant chemoradiotherapy with gemcitabine was evaluated versus cisplatin in LACC patients with comorbidities and preserved renal function. Materials and Methods An observational, longitudinal and paired study was carried out that included patients treated between February 2003 and December 2015. The primary objectives were to evaluate response rates, progression-free survival, and overall survival; the secondary objectives were to evaluate toxicity and renal function. Results Sixty-three patients treated with gemcitabine at 300 mg/m2 weekly and 126 patients treated with CDDP 40 mg/m2 weekly were included. There were no significant differences in response rates and survival rates. Treatment with cisplatin presented a higher frequency of hematological toxicities, while gemcitabine presented a higher frequency of gastrointestinal toxicities. A decrease in glomerular filtration rate (GFR; baseline vs. 1-year post-treatment) was observed in the cisplatin group (p=0.002), while not in the gemcitabine group (p=0.667). In a multivariate analysis, it is observed that only CDDP correlates with the decrease in GFR (hazard ratio, 2.42; p=0.012). Conclusion In LACC patients with comorbidities, gemcitabine and CDDP show the same efficacy, with different toxicity profiles. Treatment with cisplatin is associated with a significant decrease in GFR during follow-up, compared to treatment with gemcitabine that does not decrease it. PurposeThe standard treatment for locally advanced cervical cancer (LACC) is concomitant chemoradiotherapy with cisplatin (CDDP) followed by brachytherapy. The presence of comorbidities are risk factors for nephrotoxicity and are associated with lower survival. Gemcitabine is a radiosensitizing drug that has shown efficacy and safety in this context. The effectiveness of concomitant chemoradiotherapy with gemcitabine was evaluated versus cisplatin in LACC patients with comorbidities and preserved renal function. Materials and MethodsAn observational, longitudinal and paired study was carried out that included patients treated between February 2003 and December 2015. The primary objectives were to evaluate response rates, progression-free survival, and overall survival; the secondary objectives were to evaluate toxicity and renal function. ResultsSixty-three patients treated with gemcitabine at 300 mg/m2 weekly and 126 patients treated with CDDP 40 mg/m2 weekly were included. There were no significant differences in response rates and survival rates. Treatment with cisplatin presented a higher frequency of hematological toxicities, while gemcitabine presented a higher frequency of gastrointestinal toxicities. A decrease in glomerular filtration rate (GFR; baseline vs. 1-year post-treatment) was observed in the cisplatin group (p=0.002), while not in the gemcitabine group (p=0.667). In a multivariate analysis, it is observed that only CDDP correlates with the decrease in GFR (hazard ratio, 2.42; p=0.012).ConclusionIn LACC patients with comorbidities, gemcitabine and CDDP show the same efficacy, with different toxicity profiles. Treatment with cisplatin is associated with a significant decrease in GFR during follow-up, compared to treatment with gemcitabine that does not decrease it.

Yacon-Based Product in the Modulation of Intestinal Constipation

Moˆnica de Souza Lima Sant’Anna,Vivian Carolina Rodrigues,Tatiane Ferreira Arau´jo,Taˆnia Toledo de Oliveira,Maria do Carmo Gouveia Peluzio,Ce´lia Lu´cia de Luces Fortes Ferreira 한국식품영양과학회 2015 Journal of medicinal food Vol.18 No.9

This study aimed to assess the effects of a yacon-based product (YBP) on constipation in adults, including the elderly. Forty-eight individuals were recruited and divided into equal intervention groups named the test and control groups. The YBP (test) and the control (maltodextrin) were dissolved in commercial orange juice. The volunteers for the YBP/test group consumed, on a daily basis, orange juice containing 10 g fructooligosaccharide (FOS)/inulin per day. The control group consumed, on a daily basis, orange juice containing 25 g of maltodextrin. The study had a span of 30 days. We evaluated the participants’ frequency of evacuation, consistency of the feces, constipation score, abdominal symptoms (flatulence, pain, and abdominal strain), and effects upon the microbiota, pH, lactate, and short-chain fatty acids (SCFAs) of the feces. The study showed an increased number of evacuations after the consumption of the YBP as well as an improvement in the consistency of the feces and a reduction in the constipation score. After 30 days of intervention, the group that consumed the YBP showed higher counts of Bifidobacterium, lower Clostridium and enterobacteria counts, and lower fecal pH. In relation to SCFAs, no significant change was found after the intervention. However, the lactate concentration was higher in the test group when compared to the post-treatment control group. The YBP was effective in improving constipation symptoms; not only was its functional characteristic in reducing constipation symptoms evident but it also demonstrated usefulness as a potential therapy.

Control of plasma profiles in DIII-D discharges

Gohil, P,Evans, T E,Ferron, J R,Moyer, R A,Petty, C C,Burrell, K H,Casper, T A,Garofalo, A M,Hyatt, A W,Jayakumar, R J,Kessel, C,Kim, J Y,La Haye, R J,Lohr, J,Luce, T C,Makowski, M A,Mazon, D,Menard, Published jointly by The Institute of Physics and 2006 Plasma physics and controlled fusion Vol.48 No.a5

<P>Active control of plasma profiles is an essential requirement for operating within plasma stability limits, for steady-state operation and for optimization of the plasma performance. In DIII-D, plasma profiles have been actively controlled using various actuators in the following manner: (a) real time closed loop control of the <I>q</I> profile evolution using electron cyclotron heating and neutral beam injection as actuators; (b) active control of the density and pressure profiles in quiescent H-mode and quiescent double barrier plasmas using electron cyclotron current drive (ECCD) and pellet injection; (c) active control of the edge profiles to suppress edge localized modes using resonant magnetic perturbation with toroidal mode number <I>n</I> = 3, (d) real time control of the current density profile to suppress neoclassical tearing modes using localized deposition of co-ECCD.</P>

CHILES: H i morphology and galaxy environment at <i>z</i> = 0.12 and <i>z</i> = 0.17

Hess, Kelley M,Luber, Nicholas M,Ferná,ndez, Ximena,Gim, Hansung B,van Gorkom, J H,Momjian, Emmanuel,Gross, Julia,Meyer, Martin,Popping, Attila,Davies, Luke J M,Hunt, Lucas,Kreckel, Kathryn,Luce Oxford University Press 2019 MONTHLY NOTICES- ROYAL ASTRONOMICAL SOCIETY Vol.484 No.2